The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study

Osamu Nemoto, M. Furue, H. Nakagawa, M. Shiramoto, R. Hanada, S. Matsuki, S. Imayama, M. Kato, I. Hasebe, K. Taira, M. Yamamoto, R. Mihara, K. Kabashima, T. Ruzicka, J. Hanifin, Y. Kumagai

Research output: Contribution to journalArticlepeer-review

113 Scopus citations

Fingerprint

Dive into the research topics of 'The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study'. Together they form a unique fingerprint.

Medicine & Life Sciences